Sunitha Malepati

Sunitha Malepati is the founder of the Buffalo Initiative, a patient-led effort to advance drug development for ultra-rare diseases that operates as a program of Renaissance Philanthropy. Named for the way buffalo turn to face a storm head-on, the initiative builds a coordinated funding and development model for therapeutic programs that the traditional pharmaceutical industry is unlikely to pursue.

An attorney by background, with experience in private investment and nonprofit law, Malepati came to the rare-disease field through her family. Her daughter was diagnosed with a CACNA1A-related neurogenetic disorder shortly before her third birthday, after nearly three years of searching for an answer. When physicians told the family there were no treatments and little research likely to change that, Malepati began investigating the science herself and concluded that the gap was not in discovery but in translation: promising research was not being moved toward therapies because the economics did not fit the standard drug-development model.

She founded the Buffalo Initiative to close that gap. Rather than fund one program at a time, the initiative bundles ultra-rare therapeutic assets into a portfolio and blends sources of capital, providing patient, long-horizon financing structured as debt or royalty-based investment so that patient organizations can carry their programs through the expensive stages of development that philanthropy alone cannot reach. Malepati also serves as vice president of the CACNA1A Foundation and on the governing board of COMBINEDBrain, a consortium advancing clinical-trial readiness for rare neurodevelopmental disorders.

Malepati appeared on Open Door Salon alongside Craig Lipset, a clinical leader for the Buffalo Initiative and a longtime drug-development innovator, for a conversation on why patient groups are increasingly becoming drug developers themselves. Her central argument was that families cannot wait for pharmaceutical companies to take interest in thousands of individually small disease populations, and that a new class of drug-development sponsor, the patient-led organization, is emerging to fill the void.

Across the conversation she made the case that these programs are not charity but a genuine, if patient, investment proposition, and that the hardest part of her work has been persuading investors to see ultra-rare drug development as a category that can sustain itself and return capital over a long horizon.